These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8601568)

  • 1. The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary.
    van der Gaast A; Verwij J; Planting AS; Stoter G; Henzen-Logmans SC
    J Cancer Res Clin Oncol; 1996; 122(3):181-85. PubMed ID: 8601568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining.
    Hainsworth JD; Wright EP; Johnson DH; Davis BW; Greco FA
    J Clin Oncol; 1991 Nov; 9(11):1931-8. PubMed ID: 1941051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma.
    Torenbeek R; Lagendijk JH; Van Diest PJ; Bril H; van de Molengraft FJ; Meijer CJ
    Histopathology; 1998 Jan; 32(1):20-7. PubMed ID: 9522212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical staining for thyroid transcription factor-1: a helpful aid in discerning primary site of tumor origin in patients with brain metastases.
    Srodon M; Westra WH
    Hum Pathol; 2002 Jun; 33(6):642-5. PubMed ID: 12152164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.
    Hainsworth JD; Johnson DH; Greco FA
    Ann Intern Med; 1988 Sep; 109(5):364-71. PubMed ID: 2841895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic adenocarcinoma of unknown primary origin.
    Hammar SP
    Hum Pathol; 1998 Dec; 29(12):1393-402. PubMed ID: 9865824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoma of unknown primary: identification of a treatable subset?
    van der Gaast A; Verweij J; Henzen-Logmans SC; Rodenburg CJ; Stoter G
    Ann Oncol; 1990; 1(2):119-22. PubMed ID: 1706613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site.
    Hainsworth JD; Lennington WJ; Greco FA
    J Clin Oncol; 2000 Feb; 18(3):632-5. PubMed ID: 10653878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes.
    Roh MS; Hong SH
    J Korean Med Sci; 2002 Aug; 17(4):512-7. PubMed ID: 12172048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Dial TW; Greco FA
    Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
    Greco FA; Hainsworth JD
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.
    Bellizzi AM
    Adv Anat Pathol; 2013 Sep; 20(5):285-314. PubMed ID: 23939147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desmosomes and microvilli mean a lot: diagnosis of neoplasms of unknown origin using electron microscopy.
    Jackson SB; Strausbauch PH; Finley JL; Laich D; Hewan-Lowe KO
    Ultrastruct Pathol; 2003; 27(3):155-61. PubMed ID: 12775506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
    Van Eeden S; Quaedvlieg PF; Taal BG; Offerhaus GJ; Lamers CB; Van Velthuysen ML
    Hum Pathol; 2002 Nov; 33(11):1126-32. PubMed ID: 12454818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
    Lenzi R; Hess KR; Abbruzzese MC; Raber MN; Ordoñez NG; Abbruzzese JL
    J Clin Oncol; 1997 May; 15(5):2056-66. PubMed ID: 9164218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistological studies in five patients with unknown primary carcinomas and poorly differentiated neoplasms.
    Greenberg BR
    Ann Clin Lab Sci; 1989; 19(3):175-83. PubMed ID: 2658727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
    Hainsworth JD; Greco FA
    Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
    Hainsworth JD; Johnson DH; Greco FA
    J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1.
    Karavasilis V; Malamou-Mitsi V; Briasoulis E; Tsanou E; Kitsou E; Kalofonos H; Fountzilas G; Fotsis T; Pavlidis N
    BMC Cancer; 2005 Mar; 5():25. PubMed ID: 15743540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.